Study of new treatment for Richter’s transformation
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug (ONO-4538) for people with Richter's transformation, a rare and aggressive lymphoma that can happen to people with CLL or SLL. It aims to see if the drug can help when standard treatments have stopped working or aren't an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Richter's transformation (either DLBCL-type or Hodgkin lymphoma-type)
- You have a history of CLL or SLL
- For DLBCL-type, you have tried other treatments that didn't work, caused side effects, or you can't take them
- You have at least one tumor that can be measured on scans
- You are able to care for yourself and are up and about more than half of your waking hours (ECOG 0 or 1)
- Your doctor expects you to live at least 3 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called glofitamab, alone or combined with other drugs, for people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has changed into a faster-growing lymphoma (Richter's transformation). The goal is to see how well these treatments work and which combination might be best.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This Phase 2 study tests zanubrutinib plus tislelizumab, with or without sonrotoclax, for people whose CLL has changed into Richter transformation (an aggressive lymphoma). It aims to improve anti-cancer response while tracking side effects and safety.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
This trial tests a combination of four drugs for people whose chronic lymphocytic leukemia (CLL) has transformed into a more aggressive lymphoma called Richter syndrome. The goal is to see if this combination can control the cancer and improve outcomes.
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
Hear when a new Richter's Transformation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.